Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

NEW YORK — Oxford BioDynamics reported on Wednesday a 24 percent drop in revenues for its fiscal year 2019 amid a decline in revenues generated in the US.

For the 12-month period ended Sept. 30, the UK-based company's revenues — which were generated entirely from epigenetic biomarker research and development alliances with commercial and academic partners — fell to £907,000 ($1.2 million) from £1.2 million in the same period last year. US revenues were down 69 percent to £126,000 from £405,000, while revenues generated in the rest of the world were flat at £781,000.

"Not only have we signed additional collaboration agreements [in 2019], but we have also seen EpiSwitch [biomarker technology] being used in high profile UK and US clinical trials," Oxford BioDynamics CEO Christian Hoyer Millar said in a statement. "We believe there is significant potential for EpiSwitch biomarkers to benefit a range of diseases, but we have been particularly pleased with the progress we have announced in [immuno-oncology.]"

Earlier this year, Oxford BioDynamics announced that its EpiSwitch test for prostate cancer will be evaluated in a nearly 300-patient study in the UK.

Oxford BioDynamics' fiscal 2019 net loss grew to £2.8 million, or £.03 per share, from £2.0 million, or £.02 per share, the year before.

R&D spending declined 32 percent to £468,000 from £693,000, while general and administrative costs grew 27 percent to £1.4 million from £1.1 million.

At the end of September, Oxford BioDynamics had cash and cash equivalents totaling £5.2 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.